Development and validation of a prognostic model for survival in patients treated with venoarterial extracorporeal membrane oxygenation: the PREDICT VA-ECMO score.


Journal

European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 14 7 2018
medline: 18 12 2019
entrez: 14 7 2018
Statut: ppublish

Résumé

Several scoring systems have been introduced for prognostication after initiating venoarterial extracorporeal membrane oxygenation (VA-ECMO) therapy. However, static scores offer limited guidance once VA-ECMO is implanted, although continued allocation of healthcare resources is critical. Patients requiring continued VA-ECMO support are extremely unstable, with minimal heart function and multi-organ failure in most cases. The aim of the present study was to develop and validate a dynamic prognostic model for patients treated with VA-ECMO. A derivation cohort included 205 all-comers undergoing VA-ECMO implantation at a tertiary referral hospital (51% received VA-ECMO during resuscitation and 43% had severe shock). Two prediction models based on point-of-care biomarkers were developed using penalised logistic regression in an elastic net approach. A validation cohort was recruited from an independent tertiary referral hospital. Comparators for the prediction of hospital survival were the SAVE score (area under the receiver operation characteristic curve (AUC) of 0.686), the SAPS score (AUC 0.679), the APACHE score (AUC 0.662) and the SOFA score (AUC 0.732) in 6-hour survivors. The 6-hour PREDICT VA-ECMO score (based on lactate, pH and standard bicarbonate concentration) outperformed the comparator scores with an AUC of 0.823. The 12-hour PREDICT VA-ECMO integrated lactate, pH and standard bicarbonate concentration at 1 hour, 6 hours and 12 hours after ECMO insertion allowed even better prognostication (AUC 0.839). Performance of the scores in the external validation cohort was good (AUCs 0.718 for the 6-hour score and 0.735 for the 12-hour score, respectively). In patients requiring VA-ECMO therapy, a dynamic score using three point-of-care biomarkers predicts hospital mortality with high reliability. Furthermore, the PREDICT scores are the first scores for extracorporeal cardiopulmonary resuscitation patients.

Identifiants

pubmed: 30003795
doi: 10.1177/2048872618789052
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

350-359

Auteurs

Tobias Wengenmayer (T)

1 Department of Medicine III (Interdisciplinary Medical Intensive Care), University of Freiburg, Germany.
2 Department of Cardiology and Angiology I, Heart Center Freiburg University, Germany.

Daniel Duerschmied (D)

1 Department of Medicine III (Interdisciplinary Medical Intensive Care), University of Freiburg, Germany.
2 Department of Cardiology and Angiology I, Heart Center Freiburg University, Germany.

Erika Graf (E)

3 Institute for Medical Biometry and Statistics, University of Freiburg, Germany.

Marco Chiabudini (M)

3 Institute for Medical Biometry and Statistics, University of Freiburg, Germany.

Christoph Benk (C)

4 Department of Cardiovascular Surgery, University Heart Center Freiburg, Germany.

Sven Mühlschlegel (S)

1 Department of Medicine III (Interdisciplinary Medical Intensive Care), University of Freiburg, Germany.

Alois Philipp (A)

5 Department of Cardiothoracic Surgery, University Hospital Regensburg, Germany.

Matthias Lubnow (M)

6 Department of Internal Medicine II, University Hospital Regensburg, Germany.

Christoph Bode (C)

1 Department of Medicine III (Interdisciplinary Medical Intensive Care), University of Freiburg, Germany.
2 Department of Cardiology and Angiology I, Heart Center Freiburg University, Germany.

Dawid Leander Staudacher (DL)

1 Department of Medicine III (Interdisciplinary Medical Intensive Care), University of Freiburg, Germany.
2 Department of Cardiology and Angiology I, Heart Center Freiburg University, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH